Clinical trials: Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA)…
- Trial name
- cAPPricorn-1 (NCT06393712)
- Testing
- ALN-APP
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 210 people
- Sponsor
- Alnylam Pharmaceuticals
Cerebral Amyloid Angiopathy
A Study of AMDX-2011P in Participants With CAA
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
- Trial name
- NCT05709314
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Stroke, Neurologic Diseases, General
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
- Trial name
- NCT00056238
- Testing
- NC-758 (Anti amyloidotic [Aß] agent)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bellus Health Inc. - a GSK company
Cerebral Amyloid Angiopathy
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain.
- Trial name
- NCT01821118
- Testing
- Ponezumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA).
- Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
- Trial name
- HCCAA (NCT07716865)
- Testing
- NACA
- Where
- Iceland
- Volunteers
- 15 people
- Sponsor
- Arctic Therapeutics